Macrophage Migration Inhibitory Factor Stimulates Angiogenic Factor Expression and Correlates With Differentiation and Lymph Node Status in Patients With Esophageal Squamous Cell Carcinoma

Objective:The objectives of this study were: 1) to examine the expression of macrophage migration inhibitory factor (MIF) in esophageal squamous cell carcinoma (ESCC); 2) to see if a relationship exists between MIF expression, clinicopathologic features, and long-term prognosis; and 3) to ascertain the possible biologic function of MIF in angiogenesis. Summary Background Data:MIF has been linked to fundamental processes such as those controlling cell proliferation, cell survival, angiogenesis, and tumor progression. Its role in ESCC, and the correlation of MIF expression and tumor pathologic features in patients, has not been elucidated. Methods:The expression of MIF in tumor and nontumor tissues was examined by immunohistochemical staining. Concentrations of MIF, vascular endothelial growth factor (VEGF), and interleukin-8 (IL-8) in patients’ sera and in the supernatant of tumor cells culture were examined by ELISA. Correlations with clinicopathologic factors were made. Results:In 72 patients with ESCC, intracellular MIF was overexpressed in esophagectomy specimens. The expression of MIF correlated with both tumor differentiation and lymph node status. The median survival in the low-MIF expression group (<50% positively stained cancer cells on immunohistochemistry) and high expression group (≥50% positively stained cancer cells) was 28.3 months and 15.8 months, respectively (P = 0.03). The 3-year survival rates for the 2 groups were 37.7% and 12.1%, respectively. MIF expression was related to microvessel density; increased MIF serum levels also correlated with higher serum levels of VEGF. In addition, in vitro MIF stimulation of esophageal cancer cell lines induced a dose-dependent increase in VEGF and IL-8 secretion. Conclusions:These results demonstrate, for the first time, that human esophageal carcinomas express and secrete large amounts of MIF. Through its effects on VEGF and IL-8, MIF may serve as an autocrine factor in angiogenesis and thus play an important role in the pathogenesis of ESCC.

[1]  T. Kuroki,et al.  Molecular and cellular features of esophageal cancer cells , 2005, Journal of Cancer Research and Clinical Oncology.

[2]  L. Sobin,et al.  TNM classification: clarification of number of regional lymph nodes for pN0 , 2001, British Journal of Cancer.

[3]  Y. Ozeki,et al.  Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma , 1997, Cancer.

[4]  R. Bucala,et al.  Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome , 1997, Nature Medicine.

[5]  H. Matsubara,et al.  Clinical significance of serum vascular endothelial growth factor in esophageal squamous cell carcinoma , 2001, Cancer.

[6]  D. Schadendorf,et al.  IL-8 produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. , 1993, Journal of immunology.

[7]  G. Hannon,et al.  A Proinflammatory Cytokine Inhibits P53 Tumor Suppressor Activity , 1999, The Journal of experimental medicine.

[8]  J. Bernhagen,et al.  MIF as a glucocorticoid-induced modulator of cytokine production , 1995, Nature.

[9]  K. Tracey,et al.  MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia , 1993, Nature.

[10]  Georg Breier,et al.  Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo , 1992, Nature.

[11]  R. Atkins,et al.  Macrophage migration inhibitory factor expression in human renal allograft rejection. , 1998, Transplantation.

[12]  Michael Bacher,et al.  Macrophage migration inhibitory factor: Roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma , 2003, International journal of cancer.

[13]  S. Fan,et al.  Serum Vascular Endothelial Growth Factor Predicts Venous Invasion in Hepatocellular Carcinoma : A Prospective Study , 2001, Annals of surgery.

[14]  Sobin Lh TNM classification: clarification of number of regional lymph nodes for pN0. , 2001 .

[15]  S. Todo,et al.  An antibody for macrophage migration inhibitory factor suppresses tumour growth and inhibits tumour-associated angiogenesis. , 2000, Cytokine.

[16]  M. Feith,et al.  Adenocarcinoma of the Esophagogastric Junction: Results of Surgical Therapy Based on Anatomical/Topographic Classification in 1,002 Consecutive Patients , 2000, Annals of surgery.

[17]  M. Suzuki,et al.  High expression of macrophage migration inhibitory factor in human melanoma cells and its role in tumor cell growth and angiogenesis. , 1999, Biochemical and biophysical research communications.

[18]  M. Kitajima,et al.  Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  H. Dosaka-akita,et al.  Intracellular distribution of macrophage migration inhibitory factor predicts the prognosis of patients with adenocarcinoma of the lung , 2000, Cancer.

[20]  M. Burdick,et al.  Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. , 1996, The Journal of clinical investigation.

[21]  C. Lau,et al.  De Novo Expression of Macrophage Migration Inhibitory Factor in Atherogenesis in Rabbits , 2000, Circulation research.

[22]  M. Tachibana,et al.  Prognostic Significance of Fas and Fas Ligand System-Associated Apoptosis in Gastric Cancer , 2000, Annals of Surgical Oncology.

[23]  K. Chu,et al.  Improvement in Treatment Results and Long-Term Survival of Patients With Esophageal Cancer: Impact of Chemoradiation and Change in Treatment Strategy , 2003, Annals of surgery.

[24]  K. Chayama,et al.  Clinicopathological significance of vascular endothelial growth factor (VEGF)‐C in human esophageal squamous cell carcinomas , 2001, International journal of cancer.

[25]  Y. Furukawa,et al.  Inactivation of the p53 protein in cell lines derived from human esophageal cancers , 1997, International journal of cancer.

[26]  L. Friedman,et al.  Adenocarcinoma of the Esophagogastric Junction , 1999, Digestive Diseases.

[27]  Atkins,et al.  Up‐regulation of macrophage migration inhibitory factor in acute renal allograft rejection in the rat , 1999, Clinical and experimental immunology.

[28]  J. Wong,et al.  Prognostic implication of proliferative markers MIB‐1 and PC10 in esophageal squamous cell carcinoma , 1996, Cancer.

[29]  Barbara Magi,et al.  Protein expression profiles in human breast ductal carcinoma and histologically normal tissue , 1997, Electrophoresis.

[30]  S. Law,et al.  Prevalence and predictive value of p53 mutation in patients with oesophageal squamous cell carcinomas: A prospective clinico‐pathological study and survival analysis of 70 patients , 1997, International journal of cancer.

[31]  Simon Law,et al.  The clinicopathological significance of p21 and p53 expression in esophageal squamous cell carcinoma: an analysis of 153 patients , 1999, American Journal of Gastroenterology.

[32]  J. Bernhagen,et al.  The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor , 1994, The Journal of experimental medicine.

[33]  R. Atkins,et al.  Expression of macrophage migration inhibitory factor in human glomerulonephritis. , 2000, Kidney international.

[34]  E. Ma,et al.  Establishment and characterization of HKESC-1, a new cancer cell line from human esophageal squamous cell carcinoma. , 2000, Cancer genetics and cytogenetics.

[35]  R. Bucala,et al.  Tumor growth-promoting properties of macrophage migration inhibitory factor (MIF). , 2000, Seminars in cancer biology.

[36]  R. Bucala,et al.  An Essential Role for Macrophage Migration Inhibitory Factor (MIF) in Angiogenesis and the Growth of a Murine Lymphoma , 1999, Molecular medicine.

[37]  S. Law,et al.  Establishment, characterization, karyotyping, and comparative genomic hybridization analysis of HKESC-2 and HKESC-3: two newly established human esophageal squamous cell carcinoma cell lines. , 2002, Cancer genetics and cytogenetics.

[38]  K. Meyer-Siegler,et al.  Enhanced expression of macrophage migration inhibitory factor in prostatic adenocarcinoma metastases. , 1996, Urology.

[39]  M. Tachibana,et al.  Spontaneous apoptosis in advanced esophageal carcinoma: its relation to Fas expression. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  R. Holmdahl,et al.  Macrophage migration inhibitory factor is involved in the pathogenesis of collagen type II-induced arthritis in mice. , 1997, Journal of immunology.

[41]  M. Furihata,et al.  Prognostic significance of human papillomavirus genomes (type‐16, ‐18) and aberrant expression of p53 protein in human esophageal cancer , 1993, International journal of cancer.

[42]  Y. Yang,et al.  Identification of macrophage migration inhibitory factor as a potent endothelial cell growth-promoting agent released by ectopic human endometrial cells. , 2000, The Journal of clinical endocrinology and metabolism.

[43]  S. Natsugoe,et al.  Expression of thrombomodulin in esophageal squamous cell carcinoma and its relationship to lymph node metastasis. , 1995, Cancer research.